How AI Is Changing the Evidence Playbook for Emerging Pharma
What Medical Affairs Really Cares About at Fierce JPM Week

Summary

At Fierce JPM Week, the AI conversation has shifted from buzz to practical impact. Medical Affairs teams aren’t asking if AI matters, they’re asking how it can be applied to evidence planning and evidence generation across the product lifecycle, not just at launch.

What Matters Most to Medical Affairs

Across conversations at the event, leaders emphasized:

Evidence planning earlier in the lifecycle

Aligning strategic questions with data needs before decisions solidify.

AI embedded into workflows

Moving beyond standalone pilots towards tools used day-to-day.

Faster, decision-ready evidence

Insights that directly inform strategy, not just outputs.

Trust, transparency & explainability

AI outputs must be understandable and defensible.

How AI and Data Help

AI becomes more valuable when it bridges fragmented sources like published literature, real-world data, trial registries, and open-source datasets. This helps teams quickly identify evidence gaps, surface meaningful patterns, and generate insights that support real decisions under time pressure.

Where Avira Life Sciences Fits

01

Structuring evidence strategies that connect scientific questions with stakeholder needs.
02

Turning fragmented data into decision-ready evidence, not just documentation.
03

Using AI to accelerate insights while preserving scientific rigor and explainability.

Leave A Comment

We have expertise in providing professional services and solutions in the areas of Business & Consultancy services.